Biogen (BIIB) was upgraded by Piper Sandler from "neutral" to "overweight".
Biogen (BIIB) had its price target lowered by Truist Financial Corporation from $193.00 to $189.00. They now have a "hold" rating on the stock.
Biogen (BIIB) had its price target lowered by Citigroup Inc. from $215.00 to $190.00. They now have a "neutral" rating on the stock.
Biogen (BIIB) was upgraded by Argus to "hold".
Biogen (BIIB) had its price target raised by Morgan Stanley from $190.00 to $200.00. They now have an "equal weight" rating on the stock.